MedPath

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Phase 3
Terminated
Conditions
Type 2 Diabetes
Interventions
Drug: ITCA 650 (exenatide in DUROS)
Registration Number
NCT01785771
Lead Sponsor
Intarcia Therapeutics
Brief Summary

An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c \>10% \</=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Men or women age 18 to 80 years with type 2 diabetes
  • On stable treatment regimen of diet and exercise alone or in combination with a stable & optimal or near-optimal dose of metformin, sulfonylurea, TZD or combination of these drugs
  • HbA1c >10.0% and ≤12.0%
Exclusion Criteria
  • Prior treatment with any GLP-1 receptor agonist
  • History of hypersensitivity to exenatide or liraglutide
  • FPG >300 mg/dL
  • History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2
  • Taking DPP-4 inhibitors, incretin mimetics, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
  • history of pancreatitis

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
ITCA 650ITCA 650 (exenatide in DUROS)-
Primary Outcome Measures
NameTimeMethod
Change in HbA1c between Week 39 and Day 039 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (49)

Alabama Clinical Therapeutics, LLC

🇺🇸

Birmingham, Alabama, United States

Fundamental Research

🇺🇸

Gulf Shores, Alabama, United States

East Valley Family Physicians, PLC

🇺🇸

Chandler, Arizona, United States

Desert Clinical Research

🇺🇸

Mesa, Arizona, United States

Clinical Research Advantage, Inc.

🇺🇸

Phoenix, Arizona, United States

eStudySite

🇺🇸

Chula Vista, California, United States

Rocks Medical Research Institute, Inc.

🇺🇸

Fresno, California, United States

Rocks Medical Research Institute

🇺🇸

Fresno, California, United States

Long Beach Center for Clinical Research

🇺🇸

Long Beach, California, United States

Saviers Medical Group

🇺🇸

Port Hueneme, California, United States

Scroll for more (39 remaining)
Alabama Clinical Therapeutics, LLC
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.